NanoViricides Story

<div class='circular--portrait' style='background:#9CBEFD;color: #ffffff;font-size:4em;'>NI</div>
NNVC -- USA Stock  

USD 3.35  0.07  2.13%

NanoViricides NEW is scheduled to announce its earnings tomorrow. The stock is undergoing a sell-off trend. NanoViricides Inc Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 18.36 Million. The current year Average Equity is expected to grow to about 17.6 M, whereas Net Income Per Employee is forecasted to decline to (1.8 M). As many investors are getting excited about healthcare space, it is fair to go over NanoViricides Inc NEW as an investment option.
Published over two weeks ago
View all stories for NanoViricides Inc | View All Stories
Continue to hold NanoViricides (NYSEMKT:NNVC) based on its current debt obligations?
The company currently holds 1.11 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest NanoViricides Inc is not taking enough advantage from borrowing. NanoViricides NEW has a current ratio of 11.56, suggesting that it is liquid enough and is able to pay its financial obligations when due.
NanoViricides Inc financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of NanoViricides Inc, including all of NanoViricides Inc's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of NanoViricides Inc assets, the company is considered highly leveraged. Understanding the composition and structure of overall NanoViricides Inc debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding NanoViricides Total Debt

NanoViricides NEW liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. NanoViricides NEW has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on NanoViricides Inc balance sheet include debt obligations and money owed to different NanoViricides Inc vendors, workers, and loan providers. Below is the chart of NanoViricides main long-term debt accounts currently reported on its balance sheet.
You can use NanoViricides Inc NEW financial leverage analysis tool to get a better grip on understanding its financial position

How important is NanoViricides Inc's Liquidity

NanoViricides Inc financial leverage refers to using borrowed capital as a funding source to finance NanoViricides Inc NEW ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NanoViricides Inc financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between NanoViricides Inc's total debt and its cash.

Payment of 38472 shares by Eugene Seymour of NanoViricides Inc subject to Rule 16b-3

Legal trades by NanoViricides Inc insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
NanoViricides insider trading alert for payment of common stock par value $0.001 per share by Eugene Seymour, Chief Executive Officer, on 14th of December 2020. This event was filed by Nanoviricides Inc with SEC on 2015-09-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another angle On NanoViricides Inc

Net Loss for the year was (14.2 M) with profit before overhead, payroll, taxes, and interest of 0.

Asset Breakdown

10.3 M
Assets Non Current
13.5 M
Current Assets
Total Assets28.13 Million
Current Assets13.46 Million
Assets Non Current10.26 Million
Goodwill351,661

Are you still ambivalent about NanoViricides Inc?

The risk adjusted performance is down to -0.15 as of today. NanoViricides Inc NEW exhibits very low volatility with skewness of -0.09 and kurtosis of 1.12. However, we advise investors to further study NanoViricides Inc NEW technical indicators to make sure all market info is available and is reliable.

Our Final Take On NanoViricides Inc

Whereas some other entities in the biotechnology industry are either recovering or due for a correction, NanoViricides may not be as strong as the others in terms of longer-term growth potentials. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither take in nor sell any shares of NanoViricides Inc at this time. The NanoViricides Inc NEW risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to NanoViricides Inc.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of NanoViricides Inc NEW. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com